Advertisement

Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series

  • Oren PasvolskyEmail author
  • Adi Zoref-Lorenz
  • Uri Abadi
  • Karyn Revital Geiger
  • Lucille Hayman
  • Iuliana Vaxman
  • Pia Raanani
  • Avi Leader
Original Article

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory syndrome, which can manifest either secondary to a variety of underlying causes, or due to a primary genetic defect. Malignancy is the most common underlying disease in adults with HLH, with lymphomas being the most common malignancy. Lymphoma-associated hemophagocytic syndrome (LAHS) typically follows a rapidly progressive clinical course and is associated with poor prognosis. We herein present four patients with HLH associated with aggressive lymphoma. At initial presentation, the underlying etiology of the HLH was unclear. Two patients were eventually diagnosed with anaplastic large cell lymphoma, while the other two had diffuse large B cell lymphoma. Two of the patients experienced rapid clinical deterioration, one at diagnosis and the other at relapse, and both died prior to diagnosis of lymphoma despite HLH-directed therapy. These cases highlight the need for intensive management in adults with HLH without a clear etiology, especially in cases when lymphoma-associated HLH is suspected. We describe the current pitfalls in diagnosis and treatment of LAHS and discuss possible ways to improve patient management.

Keywords

Hemophagocytic lymphohistiocytosis T cell lymphoma B cell lymphoma Malignancy 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503–16.CrossRefGoogle Scholar
  2. 2.
    Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefGoogle Scholar
  3. 3.
    Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematol Am Soc Hematol Educ Progr. 2013;2013:605–11.CrossRefGoogle Scholar
  4. 4.
    Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125:2908–14.CrossRefGoogle Scholar
  5. 5.
    Machaczka M, Vaktnas J, Klimkowska M, Hagglund H. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma. 2011;52:613–9.CrossRefGoogle Scholar
  6. 6.
    Vick EJ, Patel K, Prouet P, Martin MG. Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy. Blood Adv. 2017;1:779–91.CrossRefGoogle Scholar
  7. 7.
    Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G, Histocyte S. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367–73.CrossRefGoogle Scholar
  8. 8.
    Riviere S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O, Fardet L. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014;127:1118–25.CrossRefGoogle Scholar
  9. 9.
    Veerakul G, Sanpakit K, Tanphaichitr VS, Mahasandana C, Jirarattanasopa N. Secondary hemophagocytic lymphohistiocytosis in children: an analysis of etiology and outcome. J Med Assoc Thai. 2002;85(Suppl 2):530–41.Google Scholar
  10. 10.
    Lehmberg K, Nichols KE, Henter JI, Girschikofsky M, Greenwood T, Jordan M, Kumar A, Minkov M, La Rosee P, Weitzman S. Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte S: Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica. 2015;100:997–1004.Google Scholar
  11. 11.
    Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, Yamamoto K, Horiuchi H, Takada K, Ohshima K, Nakamura S, Kinukawa N, Oshimi K, Kawa K. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86:58–65.CrossRefGoogle Scholar
  12. 12.
    Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Muller I, Suttorp M, Bernig T, Beutel K, Bode SF, Kentouche K, Kolb R, Langler A, Minkov M, Schilling FH, Schmid I, Vieth S, Ehl S, Zur Stadt U, Janka GE. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015;170:539–49.CrossRefGoogle Scholar
  13. 13.
    Shimazaki C, Inaba T, Nakagawa M. B-cell lymphoma-associated hemophagocytic syndrome. Leuk Lymphoma. 2000;38:121–30.CrossRefGoogle Scholar
  14. 14.
    Takahashi N, Nakahachi A. Clinicopathological characteristics of adult patients with lymphoma-associated hemophagocytic syndrome in Japan. Rinsho Ketsueki. 1999;40:96–8.Google Scholar
  15. 15.
    Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613–20.CrossRefGoogle Scholar
  16. 16.
    Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016;122:2857–66.CrossRefGoogle Scholar
  17. 17.
    Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol. 2014;93:821–6.CrossRefGoogle Scholar
  18. 18.
    Chen W, Zhang S, Zhang W, Yang X, Xu J, Qiu H, Zhang X, Li J. Elevated serum adenosine deaminase levels in secondary hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2015;37:544–50.CrossRefGoogle Scholar
  19. 19.
    Kim JE, Kim CW, Park SH, Chi JG. Hemophagocytic syndrome associated with occult B-cell lymphoma: an autopsy case. J Korean Med Sci. 1998;13:77–80.Google Scholar
  20. 20.
    Chang Y, Cui M, Fu X, Han L, Zhang L, Li L, Li X, Sun Z, Wu J, Zhang X, Li Z, Nan F, Yan J, Sheng G, Zhang M. Lymphoma associated hemophagocytic syndrome: A single-center retrospective study. Oncol Lett. 2018;16:1275–84.Google Scholar
  21. 21.
    Jing-Shi W, Yi-Ni W, Lin W, Zhao W. Splenectomy as a treatment for adults with relapsed hemophagocytic lymphohistiocytosis of unknown cause. Ann Hematol. 2015;94:753–60.CrossRefGoogle Scholar
  22. 22.
    Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, La Rosee P, Kantarjian HM. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017;123:3229–40.CrossRefGoogle Scholar
  23. 23.
    Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, Shen J, Wei N, Wang Z. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126:2186–92.CrossRefGoogle Scholar
  24. 24.
    Shin HJ, Chung JS, Lee JJ, Sohn SK, Choi YJ, Kim YK, Yang DH, Kim HJ, Kim JG, Joo YD, Lee WS, Sohn CH, Lee EY, Cho GJ. Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci. 2008;23:439–44.CrossRefGoogle Scholar
  25. 25.
    Jordan M: A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a Pilot Phase 2 study in children with primary HLH. Blood. 2015;126: LBA-3.Google Scholar
  26. 26.
    Ehl S. Etoposide for HLH: the limits of efficacy. Blood. 2017;130:2692–3.CrossRefGoogle Scholar
  27. 27.
    Salluh JI, Soares M. ICU severity of illness scores: APACHE, SAPS and MPM. Curr Opin Crit Care. 2014;20:557–65.CrossRefGoogle Scholar
  28. 28.
    d’Amore F, Gaulard P, Trumper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladetto M, Committee EG. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108–115.CrossRefGoogle Scholar
  29. 29.
    Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andre M, Johnson PW, Pfreundschuh M, Ladetto M, Committee EG. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–125.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Davidoff Cancer Center, Rabin Medical Center, Institute of HematologyBeilinson HospitalPetah TikvaIsrael
  2. 2.Department of Internal Medicine BMeir Medical CenterKfar SabaIsrael
  3. 3.Hematology Institute and Blood BankMeir Medical CenterKfar SabaIsrael
  4. 4.Department of PathologyRabin Medical CenterPetah TikvaIsrael
  5. 5.Sackler School of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations